Cerium Pharmaceuticals is a clinical-stage biopharmaceutical company based in Gaithersburg, MD, dedicated to developing effective therapies for patients with kidney diseases, particularly Primary Membranous Nephropathy (PMN). With a focus on addressing this rare kidney disease, Cerium aims to provide much-needed treatment options for the approximately 75,000 PMN patients in the US, who experience excess protein in the urine, decreased kidney function, and a significant decline in their quality of life.
Through their research and development efforts, Cerium Pharmaceuticals is working towards initiating a Phase 3 clinical trial for PMN in Q2 2022, with the goal of obtaining FDA approval for their investigational drug product. Their commitment to rare diseases and their pursuit of innovative therapies highlight their dedication to improving the lives of patients suffering from kidney diseases.
Generated from the website